RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Metabolon, Inc., a diagnostics and services company offering the industry’s leading biochemical profiling technology, announced today that it has opened a new metabolomics lab in Shanghai, China in collaboration with Shanghai Jiao Tong University (SJTU).
The SJTU-Metabolon Joint Metabolomics Laboratory is a partnership with Shanghai Jiao Tong University, one of the oldest and most prestigious public research universities in China. Metabolon has licensed its proprietary metabolomics platform technology to SJTU to enable a world class biochemical profiling laboratory at the university. SJTU has funded the laboratory and personnel already trained by Metabolon and will work with academic and commercial scientists within China or other Asian countries to perform biochemical profiling experiments with Metabolon’s technology.
“We are very pleased to be bringing the science of metabolomics to a large untapped market such as China and the Asian continent as a whole,” said Metabolon president and CEO John Ryals, Ph.D. “Our partnership with Shanghai Jiao Tong University is further proof of Metabolon’s efforts to bring personalized medicine and metabolic biomarker research to all parts of the globe.”
“Metabolomics is an important field of study that holds great promise for plant biology, medical and nutrition needs,” said Shanghai Jiao Tong University spokesperson Professor Dabing Zhang. “We are excited to work with a company on the cutting edge of such promising healthcare technology.”
Metabolon’s world headquarters is located in Durham, NC. The company also has offices in Western Europe, including London, England and Madrid, Spain.
About Metabolon
Metabolon, Inc. has advanced the field of metabolomics by pioneering and patenting the industry’s leading biochemical biomarker discovery and profiling platform. It has developed the technology to quickly identify and measure all of the biochemicals in a biological sample through its proprietary global processing method. Through the generation and interpretation of data, this method provides a precise understanding of disease etiology and drug action, and advances personalized medicine beyond what genomics and other approaches can promise. Metabolon’s expertise is being embraced by a wide range of pharmaceutical, biotechnology, food and agricultural companies. Metabolytics, its biomarker discovery and analysis business, has completed over 320 client studies and processed over 30,000 samples for customers in 2010 alone. Building on its expertise in biochemistry understanding, Metabolon is also developing proprietary diagnostic tests to determine and track disease progression. For more information about Metabolon, please visit www.metabolon.com or contact Matt Zaske at mzaske@metabolon.com or 919-595-2200.